IL25 and colorectal carcinoma: Experimental IL-25-signaling blockade (using the D9.2 clone which also blocks human IL-25R) inhibited ILC2 production of IL-4 and IL-13, limiting the suppressive capacities of MDSCs, thereby permitting the liberation of anti-tumor T cell and IFNγ-mediated immunity and reduced CRC.